Treatment Adherence and Compliance in Children and Adolescents on ADHD Medication and Emotional Expression in Clinical Practice
| Registry | NCT00540826, acronym COMPLY |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 518 (Actual) |
| Sponsor | Eli Lilly and Company (Industry) |
| Conditions | ADHD |
| Interventions | Atomoxetine, stimulants (any approved ADHD medication) (Drug) |
| Dates | start 2007-11-01, completion 2009-06-01, first posted 2007-10-08, last updated 2009-08-27 |
| Locations | 1 site in Germany |
Related Papers Related Patents Related Grants Related Experts
All trials for ADHD All trials of Atomoxetine All trials of stimulants (any approved ADHD medication)
The primary research objective of this observational study is to evaluate treatment compliance over one year in children and adolescents who are newly initiated on medication approved for the treatment of ADHD in a routine clinical setting. Compliance will be assessed using the Pediatric Compliance Self-Rating (PCSR) Instrument. A patient will be considered as compliant at a given visit, if the PCSR score is at least 5, corresponding to taking the medication at least often.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| A | Drug: Atomoxetine | A: ADHD-patients receiving non-stimulants (e.g. atomoxetine) | |
| B | Drug: stimulants (any approved ADHD medication) | B: ADHD-patients receiving stimulants |
Sex: All, ages: 6 Years to 17 Years
Inclusion Criteria: * 6-17 years old * diagnosis of ADHD according to ICD-10 or DSM-IV criteria * new initiation onto an approved medication to treat ADHD Exclusion Criteria: * no specific exclusion criteria
| Facility | City | Country | Status |
|---|---|---|---|
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bad Homburg | Germany |